PROGRAM CHAIR
David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Boston, Massachusetts
PROGRAM OVERVIEW
This educational activity is designed for healthcare providers involved in treating patients with basal cell or cutaneous squamous cell carcinomas. Our goal is to provide information outlining the most current data on immunotherapeutic approaches to treating advanced cutaneous squamous cell or basal cell carcinoma and to outline strategies for managing patients toward achieving the best possible outcomes.
TARGET AUDIENCE
This activity is designed to meet the educational needs of dermatologists, dermatopathologists, radiation oncologists, nurse practitioners, Mohs surgeons, medical oncologists, head and neck surgeons, and the multidisciplinary care team that cares for patients with basal cell or cutaneous squamous cell carcinomas.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Review the most up-to-date clinical evidence for approved and investigational immunotherapeutic approaches to the treatment of advanced cutaneous squamous cell carcinoma or basal cell carcinoma
- Apply multidisciplinary strategies to the care of patients with advanced cutaneous squamous cell carcinoma or basal cell carcinoma, including risk assessment, communication, and patient education
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| David M. Miller, MD | Discloses receiving honoraria for participation on advisory boards from Merck, EMD Serono, Regeneron Pharmaceuticals, Inc.; Sanofi/Genzyme, Pfizer, Castle Biosciences, Checkpoint Therapeutics, Incyte, Bristol Myers Squibb, and Almirall. Dr. Miller also holds stock options from Checkpoint Therapeutics and Avstera Therapeutics. In addition, Dr. Miller has received research funding from Regeneron Pharmaceuticals, Inc.; Kartos Therapeutics, Xilio Therapeutics, NeoImmune Tech, Inc., Project Data Sphere, ECOG-ACRIN, and the American Skin Association. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP of Educational Development for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Director, Medical & Scientific Services for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Dominique Barton, B.S. BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 22, 2024
EXPIRATION DATE: October 22, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
